1. Agid, Y., Ruberg, M., Javoy-Agid, F., Hirsh, E., Raisman-Vozari, R., Vyas, S., Faucheux, B., Michel, P., Kastner, A., Blanchard, V., Damier, P., Villares, J. and Zhang, P., Are dopaminergic neurons selectively vulnerable to Parkinson's disease? In H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno (Eds.), Parkinson's Disease from Basic Research to Treatment, Advance in Neurology, Vol. 60, Raven Press, New York, 1993, pp. 148–164.
2. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice;Boireau;NeuroReport,1994
3. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease;Boka;Neurosci. Lett.,1994
4. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice;Brouillet;NeuroReport,1993
5. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;Burns;Proc. Natl. Acad. Sci. USA,1983